Daniel O's most recent trade in Gilead Sciences, Inc. was a trade of 10,000 Common Stock done at an average price of $136.8 . Disclosure was reported to the exchange on March 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 136.82 per share. | 27 Mar 2026 | 10,000 | 642,567 (0%) | 0% | 136.8 | 1,368,162 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 122,755 | 122,755 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 32,815 | 100,859 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 20,026 | 68,044 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 20,026 | 662,334 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.56 per share. | 10 Mar 2026 | 9,767 | 652,567 (0%) | 0% | 148.6 | 1,450,986 | Common Stock |
| Ameriserv Fin Inc | Daniel A. Onorato | Director | Grant, award, or other acquisition of securities at price $ 3.84 per share. | 17 Feb 2026 | 440 | 57,650 (0%) | 0% | 3.8 | 1,688 | Common Stock |
| First Business Fin Services Inc | Daniel S. Ovokaitys | Chief Information Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2026 | 595 | 9,787 (0%) | 0% | 0 | Common Stock | |
| First Business Fin Services Inc | Daniel S. Ovokaitys | Chief Information Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.36 per share. | 16 Feb 2026 | 406 | 9,381 (0%) | 0% | 58.4 | 23,694 | Common Stock |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.09 per share. | 09 Feb 2026 | 1,009 | 18,969 (0%) | 0% | 37.1 | 37,424 | Common Stock |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.08 per share. | 09 Feb 2026 | 762 | 19,978 (0%) | 0% | 37.1 | 28,255 | Common Stock |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.08 per share. | 09 Feb 2026 | 705 | 20,740 (0%) | 0% | 37.1 | 26,141 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2026 | 115,640 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 150.00 per share. | 05 Feb 2026 | 115,640 | 613,912 (0%) | 0% | 150 | 17,346,000 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.01 per share. | 05 Feb 2026 | 115,640 | 729,552 (0%) | 0% | 66.0 | 7,633,396 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 131,675 | 688,373 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.28 per share. | 03 Feb 2026 | 74,461 | 613,912 (0%) | 0% | 143.3 | 10,668,772 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 139.54 per share. | 28 Jan 2026 | 5,032 | 561,666 (0%) | 0% | 139.5 | 702,186 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 140.24 per share. | 28 Jan 2026 | 4,968 | 556,698 (0%) | 0% | 140.2 | 696,725 | Common Stock |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2026 | 2,341 | 21,445 (0%) | 0% | 0 | Common Stock | |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2026 | 2,341 | 0 | - | - | Restricted Stock Units | |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2026 | 2,286 | 2,286 | - | - | Restricted Stock Units | |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2026 | 2,286 | 19,104 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.01 per share. | 23 Jan 2026 | 115,640 | 682,338 (0%) | 0% | 66.0 | 7,633,396 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2026 | 115,640 | 115,640 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 23 Jan 2026 | 115,640 | 566,698 (0%) | 0% | 135 | 15,611,400 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 21 Jan 2026 | 9,346 | 883,964 | - | 1.8 | 16,927 | Common Stock |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2026 | 7,495 | 7,495 | - | - | Restricted Stock Units | |
| UMH Properties Inc | Daniel O. Landy | EVP and President of OZ Fund | Grant, award, or other acquisition of securities at price $ 16.15 per share. | 21 Jan 2026 | 5,000 | 99,982 (0%) | 0% | 16.2 | 80,750 | UMH Properties, Inc. |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 2,755 | 5,511 | - | - | Restricted Stock Units | |
| Princeton Bancorp Inc | Daniel J. O’Donnell | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 2,755 | 16,818 (0%) | 0% | 0 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 21 Jan 2026 | 2,689 | 881,275 | - | 1.9 | 5,066 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 450,000 | 450,000 | - | - | Employee Stock Option (right to buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 299,800 | 893,310 | - | 0 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 08 Jan 2026 | 12,941 | 598,898 | - | 1.8 | 22,832 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.82 per share. | 08 Jan 2026 | 8,143 | 611,839 | - | 1.8 | 14,815 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.73 per share. | 08 Jan 2026 | 5,388 | 593,510 | - | 1.7 | 9,307 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.99 per share. | 05 Jan 2026 | 37,755 | 619,982 | - | 2.0 | 74,981 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 05 Jan 2026 | 5,102 | 657,737 | - | 2.0 | 10,032 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 05 Jan 2026 | 4,649 | 662,839 | - | 2.0 | 9,163 | Common Stock |
| UMH Properties Inc | Daniel O. Landy | EVP and President of OZ Fund | Gift of securities by or to the insider at price $ 15.90 per share. | 05 Jan 2026 | 1,185 | 94,657 (0%) | 0% | 15.9 | 18,842 | UMH Properties, Inc. |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 83.43 per share. | 31 Dec 2025 | 660 | 3,972 (0%) | 0% | 83.4 | 55,064 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 124.83 per share. | 29 Dec 2025 | 10,000 | 566,698 (0%) | 0% | 124.8 | 1,248,272 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 10,426 | 88,070 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 10,426 | 581,629 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.34 per share. | 10 Dec 2025 | 4,931 | 576,698 (0%) | 0% | 121.3 | 598,328 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 126.84 per share. | 28 Nov 2025 | 6,788 | 571,203 (0%) | 0% | 126.8 | 861,016 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 125.91 per share. | 28 Nov 2025 | 3,212 | 577,991 (0%) | 0% | 125.9 | 404,428 | Common Stock |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 1,058 | 18,309 (0%) | 0% | - | Common Stock | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 1,058 | 0 | - | - | FY 2023 Restricted Stock Units | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.31 per share. | 28 Nov 2025 | 330 | 17,979 (0%) | 0% | 31.3 | 10,332 | Common Stock |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2025 | 7,940 | 7,940 | - | - | FY 2026 Stock Appreciation Right | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2025 | 3,360 | 3,360 | - | - | FY 2026 Restricted Stock Units | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.88 per share. | 25 Nov 2025 | 3,200 | 17,251 (0%) | 0% | 31.9 | 102,016 | Common Stock |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 856 | 1,714 | - | - | FY 2025 Restricted Stock Units | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 856 | 20,718 (0%) | 0% | - | Common Stock | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.21 per share. | 21 Nov 2025 | 267 | 20,451 (0%) | 0% | 31.2 | 8,333 | Common Stock |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2025 | 5,476 | 21,566 (0%) | 0% | - | Common Stock | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.64 per share. | 19 Nov 2025 | 1,704 | 19,862 (0%) | 0% | 30.6 | 52,211 | Common Stock |
| Arrive AI Inc | Daniel O’Toole | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 3.50 per share. | 18 Nov 2025 | 11,142 | 23,155,051 | - | 3.5 | 38,955 | Common Stock |
| Ameriserv Fin Inc | Daniel A. Onorato | Director | Grant, award, or other acquisition of securities at price $ 3.28 per share. | 17 Nov 2025 | 509 | 57,210 (0%) | 0% | 3.3 | 1,670 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 70.47 per share. | 17 Nov 2025 | 15 | 3,312 (0%) | 0% | 70.5 | 1,057 | Dividend Equivalent Unit |
| Educational Development Corp | O Daniel E Keefe | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 1.35 per share. | 14 Nov 2025 | 11,419 | 151,640 (1%) | 0% | 1.4 | 15,416 | Common Stock |
| Educational Development Corp | O Daniel E Keefe | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Nov 2025 | 9,407 | 163,059 (1%) | 0% | - | Common Stock | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 1,140 | 1,140 | - | - | FY 2024 Restricted Stock Units | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 1,140 | 16,445 (0%) | 0% | - | Common Stock | |
| Valvoline Inc | Julie M. O’Daniel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.44 per share. | 14 Nov 2025 | 355 | 16,090 (0%) | 0% | 31.4 | 11,161 | Common Stock |
| 22nd Century Grp Inc | Daniel A. Otto | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2025 | 111,439 | 111,439 | - | - | Stock option (right to buy) | |
| 22nd Century Grp Inc | Daniel A. Otto | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2025 | 37,146 | 37,871 (0%) | 0% | 0 | Common Stock | |
| Banner Corp | Daniel Everett Oxford | Executive VP, Banner Bank | Grant, award, or other acquisition of securities at price $ 60.91 per share. | 03 Nov 2025 | 1,846 | 6,316 (0%) | 0% | 60.9 | 112,440 | Common Stock, $0.01 par value per share |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 119.54 per share. | 28 Oct 2025 | 7,978 | 583,225 (0%) | 0% | 119.5 | 953,667 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 118.82 per share. | 28 Oct 2025 | 2,022 | 581,203 (0%) | 0% | 118.8 | 240,259 | Common Stock |
| Synchrony Financial | O. Daniel Colao | Director | Grant, award, or other acquisition of securities at price $ 71.05 per share. | 30 Sep 2025 | 775 | 3,297 (0%) | 0% | 71.1 | 55,064 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.47 per share. | 29 Sep 2025 | 8,039 | 593,164 (0%) | 0% | 111.5 | 896,110 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 112.42 per share. | 29 Sep 2025 | 1,961 | 591,203 (0%) | 0% | 112.4 | 220,454 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 10,427 | 606,152 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 10,427 | 98,496 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.25 per share. | 10 Sep 2025 | 4,949 | 601,203 (0%) | 0% | 115.2 | 570,372 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.63 per share. | 28 Aug 2025 | 10,000 | 595,725 (0%) | 0% | 113.6 | 1,136,300 | Common Stock |
| Ameriserv Fin Inc | Daniel A. Onorato | Director | Grant, award, or other acquisition of securities at price $ 3.01 per share. | 18 Aug 2025 | 549 | 56,701 (0%) | 0% | 3.0 | 1,653 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 71.45 per share. | 15 Aug 2025 | 11 | 2,522 (0%) | 0% | 71.5 | 786 | Dividend Equivalent Unit |
| Independent Bank Corp | Daniel F. O'Brien | Director | Sale of securities on an exchange or to another person at price $ 66.88 per share. | 14 Aug 2025 | 3,781 | 22,870 (0%) | 0% | 66.9 | 252,875 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 114.09 per share. | 28 Jul 2025 | 8,345 | 605,725 (0%) | 0% | 114.1 | 952,077 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.17 per share. | 28 Jul 2025 | 1,655 | 614,070 (0%) | 0% | 113.2 | 187,293 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.40 per share. | 30 Jun 2025 | 9,400 | 616,325 (0%) | 0% | 110.4 | 1,037,796 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 66.74 per share. | 30 Jun 2025 | 825 | 2,511 (0%) | 0% | 66.7 | 55,061 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.15 per share. | 30 Jun 2025 | 600 | 615,725 (0%) | 0% | 111.1 | 66,688 | Common Stock |
| Gossamer Bio Inc | Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| UMH Properties Inc | Daniel O. Landy | EVP and President of OZ Fund | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2025 | 50,000 | 50,000 | - | - | UMH Properties, Inc. | |
| Arrive AI Inc | Daniel O’Toole | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 13.85 per share. | 10 Jun 2025 | 434,672 | 23,143,909 | - | 13.8 | 6,020,207 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 108,923 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 630,693 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 4,968 | 625,725 (0%) | 0% | 110.1 | 546,927 | Common Stock |
| Ameriserv Fin Inc | Daniel A. Onorato | Director | Grant, award, or other acquisition of securities at price $ 2.83 per share. | 06 Jun 2025 | 9,713 | 56,152 (0%) | 0% | 2.8 | 27,498 | Common Stock |
| W & T Offshore Inc | Daniel O. Conwill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 103,448 | 103,448 | - | - | Restricted Stock Units | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 73,892 | 0 | - | - | Restricted Stock Units | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 73,892 | 147,628 (0%) | 0% | - | Common Stock | |
| Hillman Soln Corp | Daniel O'Leary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 18,893 | 74,704 | - | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.11 per share. | 30 May 2025 | 6,416 | 623,852 (0%) | 0% | 110.1 | 706,497 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.96 per share. | 30 May 2025 | 3,584 | 620,268 (0%) | 0% | 111.0 | 397,696 | Common Stock |
| Independent Bank Corp | Daniel F. O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 938 | 26,651 (0%) | 0% | 0 | Common Stock |